セファロスポリン系薬剤の世界市場（2024年版）：世代別（第一世代、第二世代、第三世代、第四世代、第五世代）、投与経路別、用途別（呼吸器系感染症、皮膚感染症、尿路感染症、その他）、地域別、国別の分析市場の洞察と予測（2019-2029年）

Global Cephalosporin Drug Market (2024 Edition): Analysis by Generation (First, Second, Third, Fourth, Fifth), Route of Administration, Application (Respiratory Tract Infection, Skin Infection, Urinary Tract Infection, Others), By Region, By Country: Market Insights and Forecast (2019-2029)

エグゼクティブ・サマリーこの調査レポートは世界のセファロスポリン製剤産業を世代別（第一世代、第二世代、第三世代、第四世代、第五世代）、投与経路別（経口、非経口）、用途別（呼吸器系感染症、皮膚感... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2024年2月1日	US$2,450 シングルユーザライセンスライセンス・価格情報注文方法はこちら	260	英語

サマリー

エグゼクティブ・サマリー

この調査レポートは世界のセファロスポリン製剤産業を世代別（第一世代、第二世代、第三世代、第四世代、第五世代）、投与経路別（経口、非経口）、用途別（呼吸器系感染症、皮膚感染症、尿路感染症、その他）、地域別（米州、欧州、アジア太平洋地域、その他）に詳細に分析しています、投与経路別（経口、非経口）、用途別（呼吸器系感染症、皮膚感染症、尿路感染症、その他）、地域別（南北アメリカ、ヨーロッパ、アジア太平洋、中東・アフリカ）、過去期間（2019-2022年）、予測期間（2023年）、予測期間（2024-2029年）について掲載しています。

この調査レポートは、地域（米州、欧州、APAC、中東アフリカ）と10カ国（米国、カナダ、英国、ドイツ、フランス、イタリア、中国、日本、韓国、インド）の詳細な分析をカバーしている。さらに、市場規模、年間成長＆潜在力分析、市場プレイヤーの競合調査、投資機会、需要予測などのデータも掲載しています。

この調査レポートは、成長指標、阻害要因、需給リスク、その他の重要な統計、市場の進化に関連する現在および将来の市場動向の完全な評価も行っています。

世界のセファロスポリン医薬品市場は、2022年の132.7億米ドルから2029年末までに219億米ドルを創出すると予測される。世界のセファロスポリン薬市場の好ましい成長要素は、細菌感染の流行、抗生物質耐性パターン、規制承認、新しい製剤の導入によって推進される。2024年から2029年の予測期間中、世界のセファロスポリン医薬品はCAGR 7.5％で拡大すると予想される。製薬会社は、耐性菌に対抗するため、先進世代のセファロスポリン製剤の開発に注力している。新世代の開発、併用療法、徐放性製剤、適応拡大など、すべてがセファロスポリン薬の進化に貢献している。

呼吸器感染症、尿路感染症、皮膚・軟部組織感染症、腹腔内感染症などの細菌感染症の世界的な発生率の高さと増加は、重要な推進要因である。セファロスポリン系薬剤は、これらの感染症の治療に一般的に処方される抗生物質であり、セファロスポリン系薬剤の需要を促進している。

世界の医薬品サプライチェーンは、パンデミックの間、閉鎖、輸送制限、工場閉鎖による混乱に直面した。これらの混乱は、セファロスポリン系薬剤を含む医薬品の生産、流通、入手に影響を与えた。しかし、影響を緩和し、必要不可欠な医薬品の継続的な供給を確保するための努力がなされた。また、パンデミックは進行中の臨床試験を中断させ、セファロスポリン医薬品の開発に関連する臨床試験を含む新たな臨床試験の開始を遅らせた。この中断は、新たなセファロスポリン製剤の導入や用途の拡大に関するスケジュールに影響を与えた可能性がある。

Global Burden of Diseases, Injuries, and Risk Factors Study (GBD)によると、上気道感染症の発生率は世界全体で170-20億に達している。現在進行中の研究では、吸入可能な製剤や新しい呼吸器デバイスなど、高度な薬物送達システムの開発が行われている。これらの技術は、セファロスポリン系薬剤の気道への標的送達を強化し、有効性を向上させ、副作用を最小限に抑えることを目的としている。

徐放性製剤は、セファロスポリン製剤を長期間にわたって徐々に放出するように設計されており、投与回数を減らすことができる。これにより、患者の服薬アドヒアランスと利便性が向上します。放出制御機構などの薬物送達技術の進歩により、治療効果の持続性が確保され、急速な薬物放出に伴う副作用のリスクが軽減される可能性があります。

医薬品製造における連続製造プロセスは、効率性、費用対効果、品質管理の面で利点がある。これらのプロセスをセファロスポリンの製造に適用することで、より合理的でスケーラブルな製造パイプラインが実現する。また、スマートパッケージングでは、RFID（Radio-Frequency Identification）やQRコードのような技術を取り入れることで、医薬品の保管状況を監視し、有効期限を追跡し、製品全体の完全性を高めることができる。これにより、ライフサイクルを通してセファロスポリン医薬品の品質と安定性が保証されます。

レポートの範囲

- 本レポートは、セファロスポリン医薬品市場を金額（USD Million）別に分析しています。

- 2019-2022年の過去期間、2023年の推定期間、2024-2029年の予測期間におけるセファロスポリン医薬品市場の分析を紹介しています。

- セファロスポリン薬市場を世代別（第一世代、第二世代、第三世代、第四世代、第五世代）に分析しています。

- セファロスポリン薬市場を投与経路別（経口、非経口）に分析しています。

- セファロスポリン薬市場を用途別（呼吸器系感染症、皮膚感染症、尿路感染症、その他）に分析しています。

- 本レポートの主要な洞察は、SWOTおよびポーターのファイブフォース分析の枠組みを通して提示されています。また、市場の魅力を地域別、サービス別、運用形態別、エンドユーザー別に紹介しています。

- また、業界の主な機会、動向、促進要因、課題についても分析しています。

- 本レポートでは、競合の動向、戦略、M&A、新製品開発などを追跡しています。ルピン・リミテッド、バクスター・インターナショナル、F.ホフマン・ラ・ロシュAG、イーライリリー・アンド・カンパニー、アボット・ラボラトリーズ、メルク・アンド・カンパニー、ノバルティス、サノフィ、ファイザー、テバ・ファーマシューティカルなどが含まれます。

ページTOPに戻る

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology

2. Strategic Recommendations

3. Global Cephalosporin Drug Market: Historic and Forecast (2019-2029)

3.1 Impact Analysis of Macro Economic Factors on Global Cephalosporin Drug Market

3.2 Pipeline Scenario

3.3 Global deaths associated with bacterial antimicrobial resistance

3.4 Epidemiology: Global Infectious Disease Prevalence

3.5 Epidemiology: Global Infectious Disease Incidence

3.6 Global Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

3.7 Degree of Impact of Covid-19 on Cephalosporin Drug Market

3.8 Global Cephalosporin Drug Market Segmentation : By Generation

3.8.1 Global Cephalosporin Drug Market, By Generation Overview

3.8.2 Global Cephalosporin Drug Market Size, By First Generation, By Value, 2019H-2029F (USD Million & CAGR)

3.8.3 Global Cephalosporin Drug Market Size, By Second Generation, By Value, 2019H-2029F (USD Million & CAGR)

3.8.4 Global Cephalosporin Drug Market Size, By Third Generation, By Value, 2019H-2029F (USD Million & CAGR)

3.8.5 Global Cephalosporin Drug Market Size, By Fourth Generation, By Value, 2019H-2029F (USD Million & CAGR)

3.8.6 Global Cephalosporin Drug Market Size, By Fifth Generation, By Value, 2019H-2029F (USD Million & CAGR)

3.9 Global Cephalosporin Drug Market Segmentation : By Route of Administration

3.9.1 Global Cephalosporin Drug Market, By Route of Administration Overview

3.9.2 Global Cephalosporin Drug Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)

3.9.3 Global Cephalosporin Drug Market Size, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)

3.10 Global Cephalosporin Drug Market Segmentation : By Application

3.10.1 Global Cephalosporin Drug Market, By Application Overview

3.10.2 Global Cephalosporin Drug Market Size, By Respiratory Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)

3.10.3 Global Cephalosporin Drug Market Size, By Skin Infection, By Value, 2019H-2029F (USD Million & CAGR)

3.10.4 Global Cephalosporin Drug Market Size, By Urinary Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)

3.10.5 Global Cephalosporin Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)

4. Global Cephalosporin Drug Market, Regional Analysis

4.1 Regional Coverage of the Study

4.2 Regional Snapshot

5. Americas Cephalosporin Drug Market: Historic and Forecast (2019-2029)

5.1 Americas Cephalosporin Drug Market: Snapshot

5.2 Americas Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.3 Americas Cephalosporin Drug Market: Key Factors

5.4 Americas Cephalosporin Drug Market: Segment Analysis

5.5 Americas Cephalosporin Drug Market Segmentation : By Generation

5.5.1 Americas Cephalosporin Drug Market, By Generation Overview

5.5.2 Americas Cephalosporin Drug Market Size, By First Generation, By Value, 2019H-2029F (USD Million & CAGR)

5.5.3 Americas Cephalosporin Drug Market Size, By Second Generation, By Value, 2019H-2029F (USD Million & CAGR)

5.5.4 Americas Cephalosporin Drug Market Size, By Third Generation, By Value, 2019H-2029F (USD Million & CAGR)

5.5.5 Americas Cephalosporin Drug Market Size, By Fourth Generation, By Value, 2019H-2029F (USD Million & CAGR)

5.5.6 Americas Cephalosporin Drug Market Size, By Fifth Generation, By Value, 2019H-2029F (USD Million & CAGR)

5.6 Americas Cephalosporin Drug Market Segmentation : By Route of Administration

5.6.1 Americas Cephalosporin Drug Market, By Route of Administration Overview

5.6.2 Americas Cephalosporin Drug Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)

5.6.3 Americas Cephalosporin Drug Market Size, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)

5.7 Americas Cephalosporin Drug Market Segmentation : By Application

5.7.1 Americas Cephalosporin Drug Market, By Application Overview

5.7.2 Americas Cephalosporin Drug Market Size, By Respiratory Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)

5.7.3 Americas Cephalosporin Drug Market Size, By Skin Infection, By Value, 2019H-2029F (USD Million & CAGR)

5.7.4 Americas Cephalosporin Drug Market Size, By Urinary Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)

5.7.5 Americas Cephalosporin Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)

5.8 Americas Cephalosporin Drug Market Segmentation : By Country

5.8.1 Americas Cephalosporin Drug Market, By Country Overview

5.8.2 United States Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.8.2.1 United States Cephalosporin Drug Market, By Generation

5.8.2.2 United States Cephalosporin Drug Market, By Route of Administration

5.8.2.3 United States Cephalosporin Drug Market, By Application

5.8.3 Canada Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.8.3.1 Canada Cephalosporin Drug Market, By Generation

5.8.3.2 Canada Cephalosporin Drug Market, By Route of Administration

5.8.3.3 Canada Cephalosporin Drug Market, By Application

5.10.4 Rest of Americas Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.10.4.1 Rest of Americas Cephalosporin Drug Market, By Generation

5.10.4.2 Rest of Americas Cephalosporin Drug Market, By Route of Administration

5.10.4.3 Rest of Americas Cephalosporin Drug Market, By Application

6. Europe Cephalosporin Drug Market: Historic and Forecast (2019-2029)

6.1 Europe Cephalosporin Drug Market: Snapshot

6.2 Europe Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.3 Europe Cephalosporin Drug Market: Key Factors

6.4 Europe Cephalosporin Drug Market: Segment Analysis

6.5 Europe Cephalosporin Drug Market Segmentation : By Generation

6.5.1 Europe Cephalosporin Drug Market, By Generation Overview

6.5.2 Europe Cephalosporin Drug Market Size, By First Generation, By Value, 2019H-2029F (USD Million & CAGR)

6.5.3 Europe Cephalosporin Drug Market Size, By Second Generation, By Value, 2019H-2029F (USD Million & CAGR)

6.5.4 Europe Cephalosporin Drug Market Size, By Third Generation, By Value, 2019H-2029F (USD Million & CAGR)

6.5.5 Europe Cephalosporin Drug Market Size, By Fourth Generation, By Value, 2019H-2029F (USD Million & CAGR)

6.5.6 Europe Cephalosporin Drug Market Size, By Fifth Generation, By Value, 2019H-2029F (USD Million & CAGR)

6.6 Europe Cephalosporin Drug Market Segmentation : By Route of Administration

6.6.1 Europe Cephalosporin Drug Market, By Route of Administration Overview

6.6.2 Europe Cephalosporin Drug Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)

6.6.3 Europe Cephalosporin Drug Market Size, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)

6.7 Europe Cephalosporin Drug Market Segmentation : By Application

6.7.1 Europe Cephalosporin Drug Market, By Application Overview

6.5.2 Europe Cephalosporin Drug Market Size, By Respiratory Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)

6.5.3 Europe Cephalosporin Drug Market Size, By Skin Infection, By Value, 2019H-2029F (USD Million & CAGR)

6.5.4 Europe Cephalosporin Drug Market Size, By Urinary Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)

6.7.5 Europe Cephalosporin Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)

6.8 Europe Cephalosporin Drug Market Segmentation : By Country

6.8.1 Europe Cephalosporin Drug Market, By Country Overview

6.8.2 United Kingdom Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.8.2.1 United Kingdom Cephalosporin Drug Market, By Generation

6.8.2.2 United Kingdom Cephalosporin Drug Market, By Route of Administration

6.8.2.3 United Kingdom Cephalosporin Drug Market, By Application

6.8.3 Germany Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.8.3.1 Germany Cephalosporin Drug Market, By Generation

6.8.3.2 Germany Cephalosporin Drug Market, By Route of Administration

6.8.3.3 Germany Cephalosporin Drug Market, By Application

6.8.4 France Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.8.4.1 France Cephalosporin Drug Market, By Generation

6.8.4.2 France Cephalosporin Drug Market, By Route of Administration

6.8.4.3 France Cephalosporin Drug Market, By Application

6.8.5 Italy Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.8.5.1 Italy Cephalosporin Drug Market, By Generation

6.8.5.2 Italy Cephalosporin Drug Market, By Route of Administration

6.8.5.3 Italy Cephalosporin Drug Market, By Application

6.8.6 Rest of Europe Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.8.6.1 Rest of Europe Cephalosporin Drug Market, By Generation

6.8.6.2 Rest of Europe Cephalosporin Drug Market, By Route of Administration

6.8.6.3 Rest of Europe Cephalosporin Drug Market, By Application

7. Asia Pacific Cephalosporin Drug Market: Historic and Forecast (2019-2029)

7.1 Asia Pacific Cephalosporin Drug Market: Snapshot

7.2 Asia Pacific Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.3 Asia Pacific Cephalosporin Drug Market: Key Factors

7.4 Asia Pacific Cephalosporin Drug Market: Segment Analysis

7.5 Asia Pacific Cephalosporin Drug Market Segmentation : By Generation

7.5.1 Asia Pacific Cephalosporin Drug Market, By Generation Overview

7.5.2 Asia Pacific Cephalosporin Drug Market Size, By First Generation, By Value, 2019H-2029F (USD Million & CAGR)

7.5.3 Asia Pacific Cephalosporin Drug Market Size, By Second Generation, By Value, 2019H-2029F (USD Million & CAGR)

7.5.4 Asia Pacific Cephalosporin Drug Market Size, By Third Generation, By Value, 2019H-2029F (USD Million & CAGR)

7.5.5 Asia Pacific Cephalosporin Drug Market Size, By Fourth Generation, By Value, 2019H-2029F (USD Million & CAGR)

7.5.6 Asia Pacific Cephalosporin Drug Market Size, By Fifth Generation, By Value, 2019H-2029F (USD Million & CAGR)

7.6 Asia Pacific Cephalosporin Drug Market Segmentation : By Route of Administration

7.6.1 Asia Pacific Cephalosporin Drug Market, By Route of Administration Overview

7.6.2 Asia Pacific Cephalosporin Drug Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)

7.6.3 Asia Pacific Cephalosporin Drug Market Size, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)

7.7 Asia Pacific Cephalosporin Drug Market Segmentation : By Application

7.7.1 Asia Pacific Cephalosporin Drug Market, By ApplicationOverview

7.7.2 Asia Pacific Cephalosporin Drug Market Size, By Respiratory Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)

7.7.3 Asia Pacific Cephalosporin Drug Market Size, By Skin Infection, By Value, 2019H-2029F (USD Million & CAGR)

7.7.4 Asia Pacific Cephalosporin Drug Market Size, By Urinary Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)

7.7.5 Asia Pacific Cephalosporin Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)

7.8 Asia Pacific Cephalosporin Drug Market Segmentation : By Country

7.8.1 Asia Pacific Cephalosporin Drug Market, By Country Overview

7.8.2 China Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.8.2.1 China Cephalosporin Drug Market, By Generation

7.8.2.2 China Cephalosporin Drug Market, By Route of Administration

7.8.2.3 China Cephalosporin Drug Market, By Application

7.8.3 Japan Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.8.3.1 Japan Cephalosporin Drug Market, By Generation

7.8.3.2 Japan Cephalosporin Drug Market, By Route of Administration

7.8.3.3 Japan Cephalosporin Drug Market, By Application

7.8.4 South Korea Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.8.4.1 South Korea Cephalosporin Drug Market, By Generation

7.8.4.2 South Korea Cephalosporin Drug Market, By Route of Administration

7.8.4.3 South Korea Cephalosporin Drug Market, By Application

7.8.5 India Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.8.5.1 India Cephalosporin Drug Market, By Generation

7.8.5.2 India Cephalosporin Drug Market, By Route of Administration

7.8.5.3 India Cephalosporin Drug Market, By Application

7.8.6 Rest of Asia Pacific Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.8.6.1 Rest of Asia Pacific Cephalosporin Drug Market, By Generation

7.8.6.2 Rest of Asia Pacific Cephalosporin Drug Market, By Route of Administration

7.8.6.3 Rest of Asia Pacific Cephalosporin Drug Market, By Application

8. Middle East and Africa Cephalosporin Drug Market: Historic and Forecast (2019-2029)

8.1 Middle East and Africa Cephalosporin Drug Market: Snapshot

8.2 Middle East and Africa Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

8.3 Middle East and Africa Cephalosporin Drug Market: Key Factors

8.4 Middle East and Africa Cephalosporin Drug Market: Segment Analysis

8.5 Middle East and Africa Cephalosporin Drug Market Segmentation : By Generation

8.5.1 Middle East and Africa Cephalosporin Drug Market, By Generation Overview

8.5.2 Middle East and Africa Cephalosporin Drug Market Size, By First Generation, By Value, 2019H-2029F (USD Million & CAGR)

8.5.3 Middle East and Africa Cephalosporin Drug Market, By Second Generation, By Value, 2019H-2029F (USD Million & CAGR)

8.5.4 Middle East and Africa Cephalosporin Drug Market Size, By Third Generation, By Value, 2019H-2029F (USD Million & CAGR)

8.5.5 Middle East and Africa Cephalosporin Drug Market, By Fourth Generation, By Value, 2019H-2029F (USD Million & CAGR)

8.5.6 Middle East and Africa Cephalosporin Drug Market, By Fifth Generation, By Value, 2019H-2029F (USD Million & CAGR)

8.6 Middle East and Africa Cephalosporin Drug Market Segmentation : By Route of Administration

8.6.1 Middle East and Africa Cephalosporin Drug Market, By Route of Administration Overview

8.6.2 Middle East and Africa Cephalosporin Drug Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)

8.6.3 Middle East and Africa Cephalosporin Drug Market Size, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)

8.7 Middle East and Africa Cephalosporin Drug Market Segmentation : By Application

8.7.1 Middle East and Africa Cephalosporin Drug Market, By Application Overview

8.7.2 Middle East and Africa Cephalosporin Drug Market Size, By Respiratory Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)

8.7.3 Middle East and Africa Cephalosporin Drug Market Size, By Skin Infection, By Value, 2019H-2029F (USD Million & CAGR)

8.7.4 Middle East and Africa Cephalosporin Drug Market Size, By Urinary Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)

8.7.5 Middle East and Africa Cephalosporin Drug Market, By Others, By Value, 2019H-2029F (USD Million & CAGR)

9. Market Dynamics

9.1 Impact Assessment of Market Dynamics on the Global Cephalosporin Drug Market

9.2 Drivers

9.3 Restraints

9.4 Trends

10. Industry Ecosystem Analysis

10.1 Porter's Five Forces Analysis

11. Competitive Positioning

11.1 Companies’ Product Positioning

11.2 Market Share of Leading Companies

11.3 Company Profiling

11.3.1 Lupin Limited

11.3.2 Baxter International

11.4.3 F. Hoffmann-La Roche AG

11.3.4 Eli Lilly and Company

11.3.5 Abbott Laboratories

11.3.6 Merck & Co., Inc.

11.3.7 Novartis

11.3.8 Sanofi

11.3.9 Pfizer

11.3.10 Teva Pharmaceutical

ページTOPに戻る

Table of Contents

Summary

Executive Summary

Azoth Analytics has released a research report titled “Global Cephalosporin Drug Market (2024 Edition)” which provides a complete analysis of the Global Cephalosporin Drug industry in terms of market segmentation By Generation (First Generation, Second Generation, Third Generation, Fourth Generation, Fifth Generation), By Route of Administration (Oral, Parenteral), By Application (Respiratory Tract Infection, Skin Infection, Urinary Tract Infection, Others), By Region (Americas , Europe, Asia-pacific, Middle-East & Africa), for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, United Kingdom, Germany, France, Italy, China, Japan, South Korea, India). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global Cephalosporin Drug Market is expected to generate USD 21.9 Billion by the end of 2029, up from USD 13.27 Billion in 2022. A favourable growth element for the global Cephalosporin Drug market is propelled by the prevalence of bacterial infections, antibiotic resistance patterns, regulatory approvals, and the introduction of new formulations. During the forecast period, 2024-2029, Global Cephalosporin Drug is expected to expand at a CAGR of 7.5%. Pharmaceutical companies have focused on developing advanced generations of Cephalosporin drugs to combat bacterial resistance. The development of new generations, combination therapies, extended-release formulations, and expanded indications all contribute to the evolving landscape of Cephalosporin drugs.

The high and growing incidence of bacterial infections worldwide, such as respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections, is a significant driving factor. Cephalosporins are commonly prescribed antibiotics for treating these infections, which fuels the demand for Cephalosporin drugs.

The global pharmaceutical supply chains faced disruptions due to lockdowns, transportation restrictions, and factory closures during the pandemic. These disruptions affected the production, distribution, and availability of pharmaceutical products, including Cephalosporin drugs. However, efforts were made to mitigate the impact and ensure a continued supply of essential medications. Also, the pandemic disrupted ongoing clinical trials and delayed the initiation of new trials, including those related to the development of Cephalosporin drugs. This interruption may have impacted the timeline for introducing new Cephalosporins or exploring their expanded uses.

According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), Globally, the incidence of Upper Respiratory Infection reached 17·2 billion. Ongoing research involves the development of advanced drug delivery systems, such as inhalable formulations or novel respiratory devices. These technologies aim to enhance the targeted delivery of cephalosporin drugs to the respiratory tract, improving efficacy and minimizing side effects.

Extended-release formulations are designed to release the cephalosporin drug gradually over an extended period, allowing for less frequent dosing. This can lead to improved patient adherence and convenience. Advances in drug delivery technologies, such as controlled-release mechanisms, ensure a sustained therapeutic effect and potentially reduce the risk of side effects associated with rapid drug release.

Continuous manufacturing processes in pharmaceutical production offer advantages in terms of efficiency, cost-effectiveness, and quality control. Applying these processes to cephalosporin production contribute to a more streamlined and scalable manufacturing pipeline. Also, Smart packaging involves incorporating technologies like RFID (Radio-Frequency Identification) or QR codes to monitor drug storage conditions, track expiration dates, and enhance overall product integrity. This ensures the quality and stability of cephalosporin drugs throughout their lifecycle.

Scope of the Report

• The report analyses the Cephalosporin Drug Market by Value (USD Million).

• The report presents the analysis of the Cephalosporin Drug Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.

• The report analyses the Cephalosporin Drug Market by Generation (First Generation, Second Generation, Third Generation, Fourth Generation, Fifth Generation).

• The report analyses the Cephalosporin Drug Market by Route of Administration (Oral, Parenteral).

• The report analyses the Cephalosporin Drug Market by Application (Respiratory Tract Infection, Skin Infection, Urinary Tract Infection, Others).

• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.

• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Lupin Limited, Baxter International, F. Hoffmann-La Roche AG, Eli Lilly and Company, Abbott Laboratories, Merck & Co., Inc., Novartis, Sanofi, Pfizer, Teva Pharmaceutical.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

Azoth Analytics社の医療・製薬分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療）の最新刊レポート

Azoth Analytics社の医療・製薬分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?